Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers

[1]  M. Rué,et al.  Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. , 2020, European journal of cancer.

[2]  A. Degnim,et al.  Mastectomy and immediate breast reconstruction in the elderly: Trends and outcomes. , 2019, Surgery.

[3]  L. Rabeneck,et al.  Performance measures of magnetic resonance imaging plus mammography in the High Risk Ontario Breast Screening Program. , 2019, Journal of the National Cancer Institute.

[4]  B. Karlan,et al.  Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers , 2018, JAMA oncology.

[5]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[6]  J. Boughey,et al.  Mastectomy and Immediate Breast Reconstruction for Cancer in the Elderly: A National Cancer Data Base Study. , 2016, Journal of the American College of Surgeons.

[7]  B. Karlan,et al.  Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers , 2017, Journal of the National Cancer Institute.

[8]  S. Narod,et al.  The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy , 2017, Breast Cancer Research and Treatment.

[9]  K. Hunt,et al.  Trends in Neoadjuvant Endocrine Therapy Use and Impact on Rates of Breast Conservation in Hormone Receptor-Positive Breast Cancer: A National Cancer Data Base Study , 2017, Annals of Surgical Oncology.

[10]  F. Cardoso,et al.  Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  A. Howell,et al.  Long-term prospective clinical follow-up after BRCA1/2 presymptomatic testing: BRCA2 risks higher than in adjusted retrospective studies , 2014, Journal of Medical Genetics.

[12]  Hester F. Lingsma,et al.  Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk , 2013, International journal of cancer.

[13]  P. Møller,et al.  Age‐specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway , 2013, Clinical genetics.

[14]  Susan L Neuhausen,et al.  The risk of breast cancer in women with a BRCA1 mutation from North America and Poland , 2012, International journal of cancer.

[15]  Rosalind Eeles,et al.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. , 2010, JAMA.

[16]  J. Oosterwijk,et al.  Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age , 2010, Breast Cancer Research and Treatment.

[17]  Giovanni Parmigiani,et al.  Meta-analysis of BRCA1 and BRCA2 penetrance. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Esserman,et al.  Genetic/familial high-risk assessment , 2010 .

[19]  O. Olopade,et al.  Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.

[20]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.